Background: Hepatocellular carcinoma (HCC) is one of the heaviest malignant burdens in China. Molecular targeting agent, sorafenib, is the main therapeutic option for antitumor therapy of advanced HCC, but it is currently too expensive for the public and its therapeutic effect does not satisfy initial expectation. Therefore, it is important to develop more effective molecular targeted therapeutic strategies for advanced HCC. 
Introduction
In China, viral hepatitis (infection by hepatitis B or hepatitis C) has a high morbidity and .80 million people suffer from hepatitis-related chronic liver diseases. [1] [2] [3] [4] [5] Despite the progress made in the current prevention approaches of hepatitis, patients suffering from chronic liver diseases have a sky-high chance of developing into hepatocellular carcinoma (HCC). [6] [7] [8] Unfortunately, due to the poor clinical diagnosis technology, most patients with HCC are not diagnosed until the disease develops into advanced stage, when radical treatments such as surgical resection and liver transplantation are not useful. [6] [7] [8] Currently, molecular targeted agent sorafenib is the first-class anticancer drug used for advanced HCC treatment. 9, 10 Although global multicenter clinical trials, such as the Oriental trial and the SHARP trial, 11, 12 have demonstrated that sorafenib treatment could prolong patient survival, there are many shortcomings of the clinical application of sorafenib: 1) only a low proportion of patients are sensitive to sorafenib and can be benefited from the treatment; 11, 12 2) for patients who are initially sensitive to sorafenib, drug resistance may occur as treatment progresses; 13 expensive, which puts a huge financial burden on patients. Therefore, it is of great clinical significance to develop new and more effective treatment strategies to improve the antitumor effect of sorafenib.
Receptor tyrosine kinase c-MET was initially discovered in human osteosarcoma, and hepatocyte growth factor (HGF) is the only known ligand of c-MET. 14, 15 Recently, multiple evidences have shown that elevated level of c-MET is found in 20%-40% cases of HCC and it is associated with high risk of metastasis and poor prognosis. [16] [17] [18] HGF regulates hepatic regeneration and hepatocyte apoptosis in normal tissues and promotes the metastasis of HCC cells. [19] [20] [21] On HCC cells, HGF binds and activates c-MET, further inducing the transduction of c-MET downstream pathways, such as Raf/MEK/ERK and AKT/ETS-1 signaling pathways, and leads to the proliferation, migration, and invasion of HCC cells. [22] [23] [24] Thus, based on the roles of c-MET in many such features of tumor cells, we hypothesized that it may participate in multidrug resistance and the clearance of antitumor agents. In this study, we used ARQ-197 (also named Tivantinib), a highly selective and non-ATP competitive inhibitor of c-MET for HCC cell treatment, and found that it inhibited the activation of c-MET, promoted apoptosis, and inhibited proliferation and metastasis of HCC cells. [25] [26] [27] [28] [29] [30] Our results revealed that ARQ-197 decelerated the clearance of sorafenib in cultured HCC cells or subcutaneous HCC tumors in nude mice, and the combination of ARQ-197 and sorafenib could upregulate the antitumor effect of sorafenib on HCC cells.
Materials and methods cell line and reagents
L-02 (a nontumor hepatic cell line) HCC cell lines, HepG2 (an HCC cells line), LM-3 (a highly aggressive HCC cell line), MHCC97-H cells (a highly aggressive HCC cell line), Hu7 (an HCC cell line), BEL-7402 (an HCC cell line), MHCC97-L (a lowly aggressive HCC cell line), and SMMC-7721 (an HCC cell line), which were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, People's Republic of China) or the National Infrastructure of Cell Line Resources, Chinese Academy of Medical Sciences (Beijing, People's Republic of China), the culture collection centers of the Chinese government, have been described in our previous publication and were maintained under conditions described in our previous work. [31] [32] [33] [34] ARQ-197 (catalog no. S2753) or sorafenib (catalog no. S7397) was purchased from Selleck Corporation (Houston, TX, USA). Dimethyl sulfoxide (DMSO) was purchased from Sigma Aldrich Corporation (St Louis, MO, USA). The usage of cell lines was permitted by the Ethics Committee, the Fifth Medical Center of the PLA General Hospital.
Quantitative polymerase chain reaction
Total RNA of HCC cells was extracted by using a PARISTM Kit (Thermo Fisher Scientific, Waltham, MA, USA) and reverse transcribed by Multiscribe™ Reverse Transcriptase (Thermo Fisher Scientific) agent. Quantitative real-time PCR (qPCR) was performed following the methods described in references. 35, 36 The level of β-actin mRNA was measured as a loading control. Primers used in qPCR experiments are listed in Table 1 .
MTT assay
ARQ-197 or sorafenib was dissolved in DMSO. Then, the drugs were diluted with DMEM (Thermo Fisher Scientific). The concentrations of ARQ-197 or sorafenib used are shown in Table 2 . HCC cells were treated with indicated concentration of drugs and MTT assay was performed. Inhibition rates and IC 50 values were calculated following the methods described in our previous studies. 37 
gene reporter luciferase assay
Luciferase reporters EBS-Luc (ETS-1 binding site luciferase reporter), direct repeat 3 (DR3)-Luc (PXR binding site DR3 luciferase reporter), and everted repeat 6 (ER6)-Luc (PXR binding site ER6 luciferase reporter) have been described in our previous work. 38, 39 HCC cells, which were treated with indicated concentrations of drugs, were harvested to analyze luciferase or β-galactosidase activities following the methods described in references. 40, 41 subcutaneous tumor
All methods or protocols of the animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of the Fifth Medical Center of the PLA General Hospital. All animal studies were performed in accordance with the UK Animals (Scientific Procedures) Act, 1986 and associated guidelines. Nude mice (T-cell deficient) mice aged 4-6 weeks were purchased from Si-Bei-Fu Biotechnology Corporation (Beijing, People's Republic of China). For subcutaneous tumor models, [42] [43] [44] MHCC97-H cells were injected into nude mice (1×10 6 cells per animal).
Pharmacokinetic experiments
The sequences and effects of PXR siRNA and ETS-1 siRNA are described in our previous work. 38, 45 The pharmacokinetic 47 For cell-based experiments, HCC cells were treated with 1 μmol/L sorafenib for 12 hours. Then the cells were harvested at indicated time points. For subcutaneous tumor experiments, HCC cells were injected into nude mice to form subcutaneous tumors. Sorafenib solution was injected into subcutaneous tumors and tissue samples were harvested at indicated time points. The collected samples were extracted by acetonitrile, and the amount of sorafenib sustained in samples was identified by liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) following the methods provided by Feng et al 47 and Shao et al. 46 in vivo antitumor effect of sorafenib
In vivo antitumor effect of sorafenib was examined in a subcutaneous tumor model following the protocols described by Jia et al 32 and An et al. 48 HCC cells were injected into nude mice (1×10 6 cells per animal) and 3-4 days after injection, mice received sorafenib (2 mg/kg) treatment. Mice were orally administered sorafenib every 2 days. After 21 days of treatment (ten times treatment), mice were harvested and the volumes or weights of tumor tissues were examined. Inhibition rates of sorafenib on tumor volumes or tumor weight were calculated following the methods described by Jia et al 32 
Results

c-MeT is highly expressed in aggressive hcc cell lines
First, in order to investigate the role of c-MET in HCC cells, we measured the expression of c-MET in both non-malignant and HCC cell lines using qPCR. As shown in Figure 1 , the expression level of c-MET in nontumor L-02 cell line was significantly lower than that in different HCC cell lines. In highly aggressive cell lines MHCC97-H and LM-3, the expression level of c-MET was significantly higher than that in less-aggressive MHCC97-L cells. Table 3 .
arQ-197 enhances the in vitro antitumor effect of sorafenib on hcc cells
To examine whether ARQ-197 enhances the antitumor effect of sorafenib on HCC cells, we performed combined treatment and MTT assay. As shown in Figure 3 , ARQ-197 treatment at IC 25 concentration enhanced the antitumor effect of sorafenib on HCC cells MHCC97-H ( Figure 3A ), LM-3 ( Figure 3B ), and HepG2 ( Figure 3C ). Moreover, ARQ-197 treatment decreased the IC 50 value of sorafenib on HCC cells (Table 4) . Therefore, ARQ-197 enhances the in vitro antitumor effect of sorafenib on HCC cells.
arQ-197 inhibits the expression of epithelial-mesenchymal transition (eMT) and multidrug resistance (MDr) related genes
To examine the working mechanism of ARQ-197, the effect of ARQ-197 on the expression of genes related to EMT and 
arQ-197 inhibits the transcription factor activities of eTs-1 and PXr
Moreover, previous work from our lab had revealed that, HGF/c-MET signaling pathway promoted sorafenib resistance by enhancing PXR downstream drug resistance-related genes' expression via interaction between PXR and ETS-1.
45
To further examine the effect of ARQ-197, luciferase experiments were performed. We transfected ETS-1 responsible gene reporter plasmid EBS-Luc or PXR responsible gene reporter plasmids DR3-Luc or ER6-Luc, respectively, and then administered ARQ-197. As shown in Figure 6 , ARQ-197 treatment inhibited the luciferase activities of EBS-Luc reporter ( Figure 6A ), DR3-Luc ( Figure 6B ), and ER6-Luc ( Figure 6C ) in a dose-dependent manner. These results indicate that ARQ-197 inhibits the expression of genes related to EMT or MDR by decreasing the transcription factor activities of ETS-1 and PXR.
arQ-197 decelerates the clearance of sorafenib in hcc cells
The clearance of sorafenib in HCC cells was examined by LC-MS/MS. As shown in Figure 7 or ETS-1 siRNA was used. As shown in Table 6 , knockdown of ETS-1 or PXR's expression decelerated the clearance of sorafenib in MHCC97-H or LM-3 cells. ARQ-197 did not affect the half-life values of sorafenib in MHCC97-H or LM-3 cells in the presence of ETS-1 siRNA or PXR siRNA (Table 6 ). These data suggest that c-MET functions in a PXR/ETS-1-dependent manner.
arQ-197 enhances the in vivo antitumor effect of sorafenib on hcc tumor model
To examine the in vivo antitumor effect of ARQ-197, we administered ARQ-197 to nude mice HCC models. As shown in Figure 8 , treatment with 3 mg/kg ARQ-197 or 2 mg/kg sorafenib or together inhibited the subcutaneous growth of MHCC97-H tumors compared to the vehicle controls. ARQ-197 treatment significantly enhanced the antitumor effect of sorafenib, compared to sorafenib alone ( Figure 8) . Therefore, as expected, ARQ-197 treatment enhanced the antitumor effect of sorafenib on HCC tumor growth.
Discussion
At present, despite the fast progress made in the research of advanced HCC, patients' prognosis or clinical outcome is still poor. [49] [50] [51] Various local therapeutic strategies including radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) can delay the disease progression and reduce the tumor burden of advanced HCC, but the recurrence of the malignancy after treatment has made treating options even narrower. [52] [53] [54] [55] These situations make chemotherapies important for advanced HCC treatment. Advanced HCC is insensitive to traditional cytotoxic chemotherapies and is featured to have MDR. 56, 57 Therefore, development of more effective molecular targeted therapy has always been the top priority of research. In the present work, we demonstrated that ARQ-197 treatment enhanced the sensitivity of HCC cells to sorafenib. Currently, combination therapies are mainly considered as combinations of different treatment strategies, such as TACE + RFA, TACE + sorafenib, or RFA + sorafenib. [58] [59] [60] [61] On the other hand, there are many reports of combined cytotoxic chemotherapy drugs and molecular targeted drugs or therapeutic antibodies. [62] [63] [64] [65] Although there are very few reports on molecular targeted agents' combination, this type of combination per se is a promising strategy for cancer treatment. For example, vemurafenib + cobimetinib, dabrafenib + trametinib, and encorafenib + binimetinib have been proved to be effective in melanoma treatment. 66 Our results show that the combination of ARQ-197 and sorafenib helped to achieve better therapeutic effect.
Sorafenib resistance may be achieved through multiple molecular mechanisms. EMT process and HGF/c-MET pathway are foremost molecular mechanisms of antitumor drug resistance, which significantly promotes the antitumor effect of drugs on cancer cells. [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] Jiao et al showed that HGF treatment induced gefitinib resistance in human lung cancer cells and miR-1-3 p or miR-206 sensitizes cells to gefitinib by inhibition of c-Met and EMT process. 78 In the present work, we found that ARQ-197 inhibited the EMT process of HCC cells and enhanced the sensitivity of HCC cells to sorafenib. Moreover, ARQ-197 also inhibited the activation of PXR, which is the key regulator for exogenous drug metabolism and detoxification in cells. 79, 80 Previous studies have also shown that sorafenib can act as a ligand/agonist for PXR during treatment, promoting the expression of PXR downstream drug resistance-related genes by inducing PXR's transcription factor activity, ultimately resulting in sorafenib resistance. 47, 81 In HCC cells, the transcription factor ETS-1, an important effector of HGF/c-MET signaling pathway, could function as a co-regulator of PXR and enhance sorafenib resistance. In the present work, we found that ARQ-197 inhibited the activation of PXR as the mechanistic explanation for the decelerated clearance of sorafenib in HCC cells. ARQ-197 decreased the expression of Cyp3a4, Mdr-1, and Utg1a9, the downstream genes of PXR, in HCC cells. MDR-1 is the most important Phase II drug-metabolizing enzyme, 82 CYP3A4 is a Phase I drug-resistance enzyme, and UTG1A9 is a Phase III drug-resistance enzyme mediating sorafenib metabolism. [83] [84] [85] It is well known that binding of HGF to c-MET induced the activation of multiple downstream metabolic pathways, including the mTOR pathway. 86 Our results extended our knowledge about HGF/c-MET in drug metabolism. Sorafenib is the first-class molecular targeted drug for advanced HCC approved by the US Food and Drug Administration. In addition to sorafenib, regorafenib and lenvatinib have recently been approved for marketing. 87, 88 Future exploration of the combination of ARQ-197 with new molecular targeted drugs such as regorafenib and lenvatinib is of great significance.
Conclusion
We report that ARQ-197 enhanced the sensitivity of HCC cells to sorafenib by decelerating the clearance of sorafenib in cultured HCC cells or subcutaneous HCC tumors in nude mice. Also, our data indicate that the combination of ARQ-197 and sorafenib can upregulate the antitumor effect of sorafenib on HCC cells. 
